首都醫(yī)科大學(xué)腫瘤學(xué)系第四屆系務(wù)委員會(huì)委員；中國非公醫(yī)療協(xié)會(huì)第一屆常務(wù)理事；中國非公立醫(yī)療機(jī)構(gòu)協(xié)會(huì)血液病專業(yè)委員會(huì)主任委員；中國非公立醫(yī)療機(jī)構(gòu)協(xié)會(huì)生物技術(shù)與細(xì)胞應(yīng)用專業(yè)委員會(huì)常務(wù)委員；中國造血干細(xì)胞捐獻(xiàn)者資料庫專家委員會(huì)委員；中國臨床腫瘤學(xué)會(huì)（CSCO）抗白血病聯(lián)盟專家委員會(huì)常務(wù)委員；中國抗癌協(xié)會(huì)第一屆血液病轉(zhuǎn)化醫(yī)學(xué)專業(yè)委員會(huì)常務(wù)委員；北京醫(yī)學(xué)教育協(xié)會(huì)第七屆理事會(huì)理事；中國非公立醫(yī)療機(jī)構(gòu)協(xié)會(huì)國際醫(yī)療旅游分會(huì)第一屆委員會(huì)常委；中國初級(jí)衛(wèi)生保健基金會(huì)造血干細(xì)胞移植專業(yè)委員會(huì)副主任委員；河北省醫(yī)療質(zhì)量學(xué)會(huì)第一屆常務(wù)理事；河北省醫(yī)療質(zhì)量學(xué)會(huì)醫(yī)院質(zhì)量評(píng)鑒分會(huì)常務(wù)理事；河北省藥學(xué)會(huì)非公立醫(yī)療機(jī)構(gòu)藥學(xué)專業(yè)委員會(huì)副主任委員；醫(yī)學(xué)界價(jià)值醫(yī)療泰山獎(jiǎng)第一屆評(píng)審專家委員會(huì)評(píng)審委員。

北京醫(yī)學(xué)院畢業(yè)后赴美，后獲得在美行醫(yī)許可。在美任住院醫(yī)后，以杰出的成績被斯坦福大學(xué)醫(yī)學(xué)中心血液病及腫瘤專科錄取為臨床Fellow，取得血液病及腫瘤專家資格。先后獲得了美國國立衛(wèi)生研究院（NIH）的兩個(gè)獎(jiǎng)包括個(gè)人的博士后研究獎(jiǎng)及醫(yī)生科學(xué)家獎(jiǎng)(K11)。研究了具有抗腫瘤免疫功能的Cytokine Induced Killer (CIK) Cells,在動(dòng)物實(shí)驗(yàn)上抗腫瘤功能顯著。后被引入中國應(yīng)用于臨床治療，是國內(nèi)最早開展的幾項(xiàng)細(xì)胞免疫治療之一。曾應(yīng)美國國家醫(yī)學(xué)會(huì)邀請(qǐng)?jiān)谀陼?huì)上報(bào)告?zhèn)€人在美成功奮斗歷程。于2012年被美國消費(fèi)者協(xié)會(huì)評(píng)選為美國杰出的血液病及腫瘤專家。具有美國血液病?？漆t(yī)師，腫瘤?？漆t(yī)生執(zhí)照以及中國行醫(yī)執(zhí)照。于2015年回國，回國后主導(dǎo)了多項(xiàng)工作及研究，在細(xì)胞免疫治療如CAR-T治療、淋巴瘤、骨髓瘤及白血病等多領(lǐng)域有深入的研究及豐富的臨床經(jīng)驗(yàn)。獲醫(yī)學(xué)界價(jià)值醫(yī)療泰山獎(jiǎng)“2021年度醫(yī)療管理獎(jiǎng)獲得者”、德醫(yī)雙馨“2021人民好醫(yī)生年度人物”、2022年三河市“最美科技工作者”等榮譽(yù)稱號(hào)。

Lu, P. H., Negrin, R.S. A novel population of expanded human CD3+, CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

J. Immunol. 1994 153;1687.

Lu, P.H., Negrin, R.S. Cellular immunotherapy following autologous hematopoietic progenitor transplantation.

Biol Blood Marrow Transplant, 1997, 3(3);113-21.

Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL, Liu SH, Wu T, Lu PH, Lu DP, Chang AH, Tong CR.High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

Leukemia, 2017 Dec;31(12):2587-2593. doi: 10.1038/leu.2017.145. Epub 2017 May 15.

Yang Zhang, Fang Wang, Xue Chen, Yu Zhang, Mingyu Wang, Hong Liu, Panxiang Cao, Xiaoli Ma, Tong Wang, Jianping Zhang, Xian Zhang, Peihua Lu#, and Hongxing Liu#.CSF3R mutations are frequently associated with abnormalities of RUNX1, CBFB,CEBPA, and NPM1 genes in acute myeloid leukemia.

Cancer, 2018 Aug;124(16):3329-3338. doi: 10.1002/cncr.31586. Epub 2018 Jun 22.

Saleem MS, Aljurf M, Srivastava A, Shamsi T, Lu PH, Hamidieh AA, El Haddad A, Hashmi SK. Challenges in managing graft-versus-host disease in developing countries: a perspective.

Bone Marrow Transplant, 2018 Sep 20. doi: 10.1038/s41409-018-0333-z. [Epub ahead of print]

Abstract:

Lu, P.H. Negrin, R.S. Interleukin-12 promotes the expansion of CD3+CD56+ killer cells derived from CD3+CD56- T cells with enhanced cytotoxicity.

Blood, 1994, Vol 84, No 10, Suppl: pp289a

Lu, P.H. Negrin, R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice.

Blood, 1993, Vol 82, No 10, Suppl:pp188a (oral presentation at ASH in Dec.1993)

Lu, P.H. Wang, Z and Negrin, R.S. Functional properties of clonal populations of CD3+CD56+ cells.  

Blood, 1996, Vol 88, No 10, Suppl:pp42b.

Lu, P.H. Wang, Z, Mehta, B and Negrin, R.S. Role of IL-12 and IL-15 in the ex vivo expansion, cytotoxicity and cytokine production of human CD3+CD56+ cells derived from T cells.

Blood, 1996, Vol 88, No 10, Suppl:pp316a.

Wang, Z, Lu, P.H. Weiner, G, Tso, Jand Negrn, R.S. Anti-CD3 X anti-1D10 bispecific antibody retargets and enhances the cytotoxicity of cytokine induced killer cells.

Blood, 1996, Vol, No 1,Suppl:pp316a.

Biping Deng, Alex Hongsheng Chang, Junfang Yang, Jing Pan, Xian Zhang, Yuehui Lin, Yanan Wu, Zhenling Deng, Peihua Lu, Tong Wu, Zhaoli Liu, Chunrong Tong. Safety and efficacy of low dose CD19-CART therapy in 47 cases with relapsed refractory B-cell acute lymphoblastic leukemia(B-ALL).

ASH, December 3-6, 2016, oral presentation.

Xian Zhang1*, Xin-An Lu2*, Min Xiong1, Jun-Fang Yang1, Jian-Ping Zhang1, Xiao-Su Zhou1, Ting He2#, Pei-Hua Lu1#, Safety and efficacy of autologous or donor-derived CD19 CAR-T Treatment in relapsed B acute lymphocytic leukemia after Allo-HSCT.

EBMT, March 18-21,2018, oral presentation.

Junfang Yang1*, Xin-An Lu2*, Xian Zhang1, Min Xiong1, Jian-Ping Zhang1, Xiao-Su Zhou1, Fei-fei Qi2, Ting He2#, Pei-Hua Lu1#, Comparison of CD19 CAR-T cells with distinct co-stimulatory domains in treatment of B-cell acute lymphoblastic leukemia.

ASCO, June 1-5,2018, presentation in the Poster Session.

Junfang Yang, Jianqiang Li, Xian Zhang, Fanyong Lv,  Xiaoling Guo, Qinglong Wang，Lin Wang，Dandan Chen，Xiaosu Zhou, Jinhai Ren, Peihua Lu#, A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia.

ASH, December 1-4, 2018, oral presentation.

Xian Zhang, Xin-an Lu, Junfang Yang, Fanyong Lv, Min Xiong, Jianping Zhang, Xiaosu Zhou, Ting He, Peihua Lu#?,Efficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden(HLB), BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse.

ASH, December 1-4, 2018, oral presentation.